Cox Louis Anthony, Huber William A
Cox Associates, Denver, CO 80218, USA.
Risk Anal. 2007 Dec;27(6):1441-53. doi: 10.1111/j.1539-6924.2007.00980.x.
Many models of exposure-related carcinogenesis, including traditional linearized multistage models and more recent two-stage clonal expansion (TSCE) models, belong to a family of models in which cells progress between successive stages-possibly undergoing proliferation at some stages-at rates that may depend (usually linearly) on biologically effective doses. Biologically effective doses, in turn, may depend nonlinearly on administered doses, due to PBPK nonlinearities. This article provides an exact mathematical analysis of the expected number of cells in the last ("malignant") stage of such a "multistage clonal expansion" (MSCE) model as a function of dose rate and age. The solution displays symmetries such that several distinct sets of parameter values provide identical fits to all epidemiological data, make identical predictions about the effects on risk of changes in exposure levels or timing, and yet make significantly different predictions about the effects on risk of changes in the composition of exposure that affect the pharmacodynamic dose-response relation. Several different predictions for the effects of such an intervention (such as reducing carcinogenic constituents of an exposure) that acts on only one or a few stages of the carcinogenic process may be equally consistent with all preintervention epidemiological data. This is an example of nonunique identifiability of model parameters and predictions from data. The new results on nonunique model identifiability presented here show that the effects of an intervention on changing age-specific cancer risks in an MSCE model can be either large or small, but that which is the case cannot be predicted from preintervention epidemiological data and knowledge of biological effects of the intervention alone. Rather, biological data that identify which rate parameters hold for which specific stages are required to obtain unambiguous predictions. From epidemiological data alone, only a set of equally likely alternative predictions can be made for the effects on risk of such interventions.
许多与暴露相关的致癌模型,包括传统的线性化多阶段模型和最新的两阶段克隆扩增(TSCE)模型,都属于一类模型,在这类模型中,细胞在连续阶段之间进展——可能在某些阶段进行增殖——其速率可能取决于(通常呈线性)生物有效剂量。反过来,由于生理药代动力学(PBPK)的非线性,生物有效剂量可能非线性地取决于给药剂量。本文对这种“多阶段克隆扩增”(MSCE)模型最后一个(“恶性”)阶段的预期细胞数量进行了精确的数学分析,该数量是剂量率和年龄的函数。该解决方案显示出对称性,使得几组不同的参数值对所有流行病学数据提供相同的拟合,对暴露水平或时间变化对风险的影响做出相同的预测,但对影响药效剂量反应关系的暴露组成变化对风险的影响做出显著不同的预测。对于仅作用于致癌过程一个或几个阶段的此类干预(例如减少暴露中的致癌成分)的效果,几种不同的预测可能同样与所有干预前的流行病学数据一致。这是模型参数和数据预测不可唯一识别的一个例子。这里给出的关于模型不可唯一识别的新结果表明,在MSCE模型中,干预对改变特定年龄癌症风险的影响可能很大,也可能很小,但仅根据干预前的流行病学数据和对干预生物效应的了解无法预测是哪种情况。相反,需要识别哪些速率参数适用于哪些特定阶段的生物学数据才能获得明确的预测。仅从流行病学数据来看,对于此类干预对风险的影响,只能做出一组同样可能的替代预测。